LERIGLITAZONE

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H20N2O4S
Molecular Weight	372.438
Optical Activity	( + / - )
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC(O)C1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1

InChI

InChIKey=OXVFDZYQLGRLCD-UHFFFAOYSA-N

InChI=1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24)

HIDE SMILES / InChI

Molecular Formula	C19H20N2O4S
Molecular Weight	372.438
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description

Hydroxypioglitazone (M-IV) is an active metabolite of the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone. Experiments in vitro have shown that hydroxypioglitazone was more efficient than the parent drug in stimulating lipid synthesis.

Approval Year

PubMed

PubMed

Show entries

Title	Date	PubMed
Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone.	1996 Dec 20	8978836
Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone, hydroxypioglitazone and metformin in human plasma by LC-MS/MS: application to a pharmacokinetic study.	2013 Jul 1	23732843
A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study.	2014 Oct 15	25195022